Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 24 of 27
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
NCT00266656
Efficacy Study of LY2422347 to Treat Insomnia
NCT00259311
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
NCT00380744
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
NCT00279214
Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease
NCT00244322
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
NCT00785538
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
NCT00207116
Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin
NCT00231725
Tadalafil in Subjects With Mild to Moderate Hypertension
NCT00157326
Duloxetine Versus Placebo in the Treatment of FMS
NCT00233025
Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
NCT00157339
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
NCT00207077
Head and Neck Cancer Registry (LORHAN)
NCT01080313
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
NCT00125918
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
NCT00110357
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
NCT00127634
A Study in People With Abnormal Fat Levels in the Blood
NCT00116519
A Study in People With High Cholesterol
NCT00133380
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
NCT00113594
A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months
NCT00333281
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
NCT00190879
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
NCT00190866
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
NCT00106002
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
NCT00105092
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
NCT00105989
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00162318
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
NCT00102804
A Trial for Patients With Advanced/Recurrent Cervical Cancer
NCT00190983
Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence
NCT00190853
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
NCT00095199
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
NCT00191412
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
NCT00122863
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
NCT00793975
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112346
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
NCT00191022
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
NCT00101842
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112294
Effects of Teriparatide on Distal Radius Fracture Healing
NCT00190944
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
NCT00162110
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00079924
Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)
NCT00099515
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00097227
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
NCT00097591
Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00097214
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
NCT00082212
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
NCT00122850
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
NCT00547625
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
NCT00083720
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
NCT00094549
A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder
NCT00191061
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.